Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

Merck KGaA acquires Silence Therapeutics for $1.3 billion

German drugmaker Merck KGaA will acquire UK-based Silence Therapeutics in an all-cash deal for approximately $1.3 billion, adding RNA-targeting medicines to its pipeline.